CN105106245A - Application of Akkermansia muciniphila BAA-835 strain - Google Patents

Abstract

The invention belongs to the application field of probiotics, in particular to Akkermansia? muciniphila? Application of the BAA-835 bacterial strain in preparing treatment or prevention of obesity. The present invention divides C57/BL6 male SPF mouse littermates into a control group and a bacterium-filled group at random, and the bacterium-filled group is given Akkermansia? muciniphila? BAA-835 strain suspension was administered orally, once a day, for 5 weeks. Through the experiment, the body weight and body fat of the bacteria injection group decreased significantly, and Akkermansiamuciniphila? The BAA-835 strain is very effective in reducing the inguinal subcutaneous fat content and the peri-epididymal fat content, so the bacterial strain can be used in the treatment or prevention of obesity.

Description

Application of Akkermansia muciniphila BAA-835 strain

technical field

The invention belongs to the application field of probiotics, in particular to the application of Akkermansiamuciniphila BAA-835 bacterial strain in treating or preventing obesity.

Background technique

Obesity, as a risk factor for type 2 diabetes, cardiovascular disease and tumors, has become a global social public problem. In the past decade, genome-wide association analysis has discovered more than 100 human obesity susceptibility loci. However, these loci Can only explain a limited number of causes of obesity. Moreover, the current effective treatment methods for obesity are still very limited. Most of the weight-loss drugs approved by the US FDA have been withdrawn from the market due to large side effects or poor effects. It is urgent to develop new weight-loss methods. Another human genome, the gut microbiota genome, encodes genes 150 times more than the genes encoded by the human own genome. This abundance determines that it may play a role in the occurrence of obesity. Studies have shown that the intestinal flora structure of obese patients is disordered, the diversity of intestinal bacteria decreases, and there is an imbalance in the ratio of Bacteroides and Firmicutes; studies based on mice have found some bacterial types that can reduce body weight, such as Bacteroides uniformis CECT77712. This article adopts the method of intragastric administration in mice. On the basis of ordinary C57BL6 mice fed with a high-fat diet, they are given sterile normal saline or bacterial suspension, and are intragastrically administered every day for 4-8 weeks. The body weight growth curve is recorded. After the test, body fat, blood sugar, serum and adipose tissue were collected. The results showed that continuous intragastric administration of the bacteria can resist obesity and body fat increase caused by high-fat diet, reduce blood sugar, and improve systemic and adipose tissue inflammation. The findings of these studies provide an important experimental basis and technical means for the development of probiotics to intervene in obesity.

Therefore, there is an urgent need in this field to develop an effective, new and non-toxic drug for the treatment and prevention of obesity-like diseases.

Contents of the invention

The purpose of the present invention is to provide the application of Akkermansiamuciniphila BAA-835 strain in the preparation of treatment or prevention of obesity, which relates to the application of medicines, pharmaceutical compositions, food and feed for treatment or prevention of obesity. The strain reduces blood sugar and improves glucose metabolism in mice. Widen the scope of use of AkkermansiamuciniphilaBAA-835 strains, and develop an effective, new, non-toxic and side effect-free application field for the treatment and prevention of obesity.

The invention relates to the application of Akkermansia muciniphila BAA-835 strain in the preparation of medicines for treating or preventing obesity. Experiments have proved that the Akkermansiamuciniphila BAA-835 strain has the beneficial effects of reducing blood sugar and improving glucose tolerance in mice. Therefore, this strain is a probiotic for obesity intervention and can be used in the preparation of drugs for treating or preventing obesity.

A pharmaceutical composition for treating or preventing obesity, characterized by comprising: Akkermansiamuciniphila BAA-835 strain and pharmaceutically acceptable auxiliary materials. Preferably, when the pharmaceutical composition for treating or preventing obesity is solid, the pharmaceutical composition contains 10 ⁷ -10 ¹² cfu/g of Akkermansia muciniphila BAA-8352 strain;

When the pharmaceutical composition for treating or preventing obesity is in a liquid state, the pharmaceutical composition contains 10 ⁷ -10 ¹¹ cfu/mL of Akkermansia muciniphila BAA-835 strain.

The pharmaceutically acceptable adjuvant is at least one selected from the group consisting of carriers, excipients, diluents, lubricants, wetting agents, emulsifiers, suspension stabilizers, preservatives, sweeteners and spices. Through animal experiments, the pharmaceutical composition can treat or prevent obesity.

The above pharmaceutical composition can be prepared as a medicine for treating or preventing obesity. Preferably, the medicine is in at least one formulation form of granules, capsules, tablets, powders, oral liquids, suspensions and emulsions.

A food for treating or preventing obesity is characterized in that it includes Akkermansiamuciniphila BAA-835 strain and food acceptable auxiliary materials. Preferably, when the food for treating or preventing obesity is solid, the food contains 10 ⁷ -10 ¹² cfu/g of Akkermansia muciniphila BAA-835 strain;

When the food for treating or preventing obesity is in a liquid state, the food contains 10 ⁷ -10 ¹¹ cfu/mL of Akkermansia muciniphila BAA-835 strain.

The food acceptable auxiliary material is at least one selected from the group consisting of carriers, excipients, diluents, lubricants, wetting agents, emulsifiers, suspension stabilizers, preservatives, sweeteners and spices.

A feed for treating or preventing obesity is characterized in that it includes Akkermansia muciniphila BAA-835 bacterial strain and acceptable auxiliary materials in feed science.

The beneficial effects of the present invention are: the present invention provides a new application of the AkkermansiamuciniphilaBAA-835 strain in the preparation of medicines for the treatment or prevention of obesity. Through experiments, it has been verified that the AkkermansiamuciniphilaBAA-835 strain is very effective in controlling body weight and body fat. The inguinal subcutaneous fat content of the group was reduced by 38.4%, and the para-epididymal fat content of the bacteria-infused group group was reduced by 31.7%, indicating that the Akkermansiamuciniphila strain is very effective in reducing the inguinal subcutaneous fat content and the para-epididymal fat content. Therefore, the Akkermansiamuciniphila BAA-835 strain can be used in medicines, pharmaceutical compositions, food and feed for treating or preventing obesity, which broadens the application field of the Akkermansiamuciniphila BAA-835 strain.

Description of drawings

Figure 1 is a comparison chart of the percentage of body weight growth in mice after 5 weeks of inoculation with bacteria.

Figure 2 is a comparison chart of the percentage of body fat in the body weight of mice after 5 weeks of bacteria injection.

Figure 3 is a comparison chart of the weight of adipose tissue in the percentage of body weight after 5 weeks of bacteria injection in mice.

Detailed ways

Below in conjunction with embodiment, the present invention will be further described:

The mouse model used in this example is: select 10-week-old C57/BL6 male SPF mice, all purchased from Shanghai Slack Animal Experiment Co., Ltd. Five mice were housed in a cage in an isolation bag, with free access to water and food, and to maintain a circadian rhythm.

Strain information: Akkermansia muciniphila BAA-835 strain was purchased from ATCC, USA, product name: Akkermansia BAA-835.

Example 1

The C57/BL6 male SPF level mice were randomly divided into control group and bacteria-filled group, with 8-10 mice in each group. The control group was given aseptic PBS, once a day; the bacteria-filled group was given AkkermansiamuciniphilaBAA-835 strain suspension according to 2*10 ⁹ cfu/mouse, intragastric administration test, once a day. Test for 5 weeks. During the period, the weight growth rate of the mice was recorded, and the lipid metabolism-related levels such as fat content were detected after the experiment.

Body weight and body fat are shown in Table 1 below.

Table 1

As can be seen from the table, after intragastric administration of the Akkermansiamuciniphila BAA-835 bacterial strain suspension to the mice, body weight and body fat were significantly slower than those in the control group, indicating that the Akkermansiamuciniphila BAA-835 bacterial strain is very effective in controlling body weight and body fat. Specifically shown in Figure 1 and Figure 2.

The subcutaneous fat content of the groin and the fat content of the epididymis of the mice were tested, and the results are shown in Table 2:

Table 2

As can be seen from Table 2, after intragastric administration of the Akkermansiamuciniphila bacterial strain suspension in mice, the subcutaneous fat content in the groin of the bacteria-infused group group decreased by 38.4%, and the para-epididymal fat content of the bacteria-infused group group decreased by 31.7%, indicating that the Akkermansiamuciniphila strain It is very effective in reducing the subcutaneous fat content of the groin and the fat content of the epididymis. Specifically shown in Figure 3.

The above description is only a preferred embodiment of the present invention, but the present invention should not be limited to the content disclosed in this embodiment. Therefore, all equivalents or modifications that do not deviate from the spirit disclosed in the present invention fall within the protection scope of the present invention.

Claims (10)

1. The application of 1.AkkermansiamuciniphilaBAA-835 bacterial strain in preparation treatment or prevention of obesity disease drug.
2. 2. the pharmaceutical composition for the treatment of or preventing obesity, is characterized in that, comprising: AkkermansiamuciniphilaBAA-835 bacterial strain and pharmaceutically acceptable adjuvant.
3. 3. treatment according to claim 2 or the pharmaceutical composition that prevents obesity, is characterized in that: when this pharmaceutical composition is solid-state, comprise 10 in described pharmaceutical composition ⁷-10 ¹²the AkkermansiamuciniphilaBAA-835 bacterial strain of cfu/g; When this pharmaceutical composition is liquid, in described pharmaceutical composition, comprise 10 ⁷-10 ¹¹the AkkermansiamuciniphilaBAA-835 bacterial strain of cfu/mL.
4. 4. treatment according to claim 3 or the pharmaceutical composition that prevents obesity, it is characterized in that, described pharmaceutically acceptable adjuvant is be selected from least one in carrier, excipient, diluent, lubricant, wetting agent, emulsifying agent, suspension stabiliser, antiseptic, sweeting agent and spice.
5. 5. the medicine for the treatment of or preventing obesity, is characterized in that, comprise the pharmaceutical composition any one of claim 2-4.
6. 6. treatment according to claim 5 or the medicine that prevents obesity, it is characterized in that, described medicine is at least one dosage form in granule, capsule, tablet, powder agent, oral liquid, suspension and Emulsion.
7. 7. the food for the treatment of or preventing obesity, is characterized in that, comprise acceptable adjuvant in AkkermansiamuciniphilaBAA-835 bacterial strain and bromatology.
8. 8. treatment according to claim 7 or the food that prevents obesity, is characterized in that, when described food is solid-state, comprise 10 in described food ⁷-10 ¹²the AkkermansiamuciniphilaBAA-835 bacterial strain of cfu/g; When this food is liquid, in described food, comprise 10 ⁷-10 ¹¹the AkkermansiamuciniphilaBAA-835 bacterial strain of cfu/mL.
9. 9. treatment according to claim 7 or the food that prevents obesity, it is characterized in that, in described bromatology, acceptable adjuvant is be selected from least one in carrier, excipient, diluent, lubricant, wetting agent, emulsifying agent, suspension stabiliser, antiseptic, sweeting agent and spice.
10. 10. the feedstuff for the treatment of or preventing obesity, is characterized in that, comprise acceptable adjuvant in AkkermansiamuciniphilaBAA-835 bacterial strain and feedstuff.